News

hex image
January 10, 2025
Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
May 20, 2024
Rila Therapeutics Announces Dosing of First Cohort in Phase 1 Clinical Trial of RLA-23174, a First-In-Class HIPK2 Allosteric Inhibitor, For Treatment of Chronic Kidney Disease and Fibrosis
November 6, 2019
MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor